tiprankstipranks
Zevra Therapeutics (ZVRA)
NASDAQ:ZVRA
US Market
ZVRA
Zevra Therapeutics
RESEARCH TOOLSreports
Want to see ZVRA full AI Analyst Report?

Zevra Therapeutics (ZVRA) Stock Forecast & Price Target

1,133 Followers
See the Price Targets and Ratings of:

ZVRA Analyst Ratings

Strong Buy
9Ratings
Strong Buy
9 Buy
0 Hold
0 Sell
Based on 9 analysts giving stock ratings to
Zevra
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ZVRA Stock 12 Month Forecast

Average Price Target

$25.25
▲(109.72% Upside)
Based on 9 Wall Street analysts offering 12 month price targets for Zevra Therapeutics in the last 3 months. The average price target is $25.25 with a high forecast of $35.00 and a low forecast of $20.00. The average price target represents a 109.72% change from the last price of $12.04.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"$7","36":"$36","14.25":"$14.25","21.5":"$21.5","28.75":"$28.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$35.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$25.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$20.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,14.25,21.5,28.75,36],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.51,11.47076923076923,13.431538461538462,15.392307692307693,17.353076923076923,19.313846153846153,21.274615384615387,23.235384615384618,25.196153846153848,27.15692307692308,29.11769230769231,31.07846153846154,33.03923076923077,{"y":35,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.51,10.72076923076923,11.931538461538462,13.142307692307693,14.353076923076923,15.563846153846153,16.774615384615384,17.985384615384618,19.196153846153848,20.40692307692308,21.61769230769231,22.82846153846154,24.03923076923077,{"y":25.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.51,10.316923076923077,11.123846153846154,11.930769230769231,12.737692307692308,13.544615384615383,14.35153846153846,15.158461538461538,15.965384615384615,16.77230769230769,17.57923076923077,18.386153846153846,19.193076923076923,{"y":20,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":11.11,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.1,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.43,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.18,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.34,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.96,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.36,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.09,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.41,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.07,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.49,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.81,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.51,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$35.00Average Price Target$25.25Lowest Price Target$20.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on ZVRA
Brandon Folkes
H.C. Wainwright
H.C. Wainwright
$26
Buy
115.95%
Upside
Reiterated
08/21/26
Zevra Therapeutics: Buy Rating Reiterated as MIPLYFFA Growth Conviction Strengthens and $26 Price Target Maintained
Canaccord Genuity Analyst forecast on ZVRA
Sumant Kulkarni
Canaccord Genuity
Canaccord Genuity
$20
Buy
66.11%
Upside
Reiterated
08/11/26
Canaccord Genuity Sticks to Its Buy Rating for Zevra Therapeutics (ZVRA)
Citizens JMP Analyst forecast on ZVRA
Jason Butler
Citizens JMP
Citizens JMP
$25→$28
Buy
132.56%
Upside
Reiterated
08/06/26
Zevra Therapeutics price target raised to $28 from $25 at CitizensZevra Therapeutics price target raised to $28 from $25 at Citizens
William Blair Analyst forecast on ZVRA
Sami Corwin
William Blair
William Blair
―
Buy
―
Reiterated
08/06/26
Zevra Pharmaceuticals: Strong Miplyffa Uptake, Arimoclomol EAP Momentum, and EU Re-examination Support Buy Rating
Guggenheim Analyst forecast on ZVRA
Eddie Hickman
Guggenheim
Guggenheim
$24→$23
Buy
91.03%
Upside
Reiterated
08/06/26
Zevra Therapeutics price target lowered to $23 from $24 at GuggenheimZevra Therapeutics price target lowered to $23 from $24 at Guggenheim
Maxim Group Analyst forecast on ZVRA
Jason McCarthy
Maxim Group
Maxim Group
$35
Buy
190.70%
Upside
Reiterated
08/06/26
Zevra: Buy Rating Reaffirmed on Strong MIPLYFFA Momentum and U.S. NPC Opportunity; Price Target Maintained at $35
Roth MKM Analyst forecast on ZVRA
Jonathan Aschoff
Roth MKM
Roth MKM
$21
Buy
74.42%
Upside
Reiterated
08/06/26
Roth MKM Sticks to Their Buy Rating for Zevra Therapeutics (ZVRA)
Cantor Fitzgerald Analyst forecast on ZVRA
Kristen Kluska
Cantor Fitzgerald
Cantor Fitzgerald
$25
Buy
107.64%
Upside
Reiterated
08/05/26
Zevra Therapeutics (ZVRA) Receives a Buy from Cantor Fitzgerald
BTIG Analyst forecast on ZVRA
Kambiz Yazdi
BTIG
BTIG
$24
Buy
99.34%
Upside
Reiterated
08/05/26
Analyst Reiterates Buy on Zevra as Strong Miplyffa Performance Offsets Arimoclomol Setback; $24 Price Target Maintained
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on ZVRA
Brandon Folkes
H.C. Wainwright
H.C. Wainwright
$26
Buy
115.95%
Upside
Reiterated
08/21/26
Zevra Therapeutics: Buy Rating Reiterated as MIPLYFFA Growth Conviction Strengthens and $26 Price Target Maintained
Canaccord Genuity Analyst forecast on ZVRA
Sumant Kulkarni
Canaccord Genuity
Canaccord Genuity
$20
Buy
66.11%
Upside
Reiterated
08/11/26
Canaccord Genuity Sticks to Its Buy Rating for Zevra Therapeutics (ZVRA)
Citizens JMP Analyst forecast on ZVRA
Jason Butler
Citizens JMP
Citizens JMP
$25→$28
Buy
132.56%
Upside
Reiterated
08/06/26
Zevra Therapeutics price target raised to $28 from $25 at CitizensZevra Therapeutics price target raised to $28 from $25 at Citizens
William Blair Analyst forecast on ZVRA
Sami Corwin
William Blair
William Blair
―
Buy
―
Reiterated
08/06/26
Zevra Pharmaceuticals: Strong Miplyffa Uptake, Arimoclomol EAP Momentum, and EU Re-examination Support Buy Rating
Guggenheim Analyst forecast on ZVRA
Eddie Hickman
Guggenheim
Guggenheim
$24→$23
Buy
91.03%
Upside
Reiterated
08/06/26
Zevra Therapeutics price target lowered to $23 from $24 at GuggenheimZevra Therapeutics price target lowered to $23 from $24 at Guggenheim
Maxim Group Analyst forecast on ZVRA
Jason McCarthy
Maxim Group
Maxim Group
$35
Buy
190.70%
Upside
Reiterated
08/06/26
Zevra: Buy Rating Reaffirmed on Strong MIPLYFFA Momentum and U.S. NPC Opportunity; Price Target Maintained at $35
Roth MKM Analyst forecast on ZVRA
Jonathan Aschoff
Roth MKM
Roth MKM
$21
Buy
74.42%
Upside
Reiterated
08/06/26
Roth MKM Sticks to Their Buy Rating for Zevra Therapeutics (ZVRA)
Cantor Fitzgerald Analyst forecast on ZVRA
Kristen Kluska
Cantor Fitzgerald
Cantor Fitzgerald
$25
Buy
107.64%
Upside
Reiterated
08/05/26
Zevra Therapeutics (ZVRA) Receives a Buy from Cantor Fitzgerald
BTIG Analyst forecast on ZVRA
Kambiz Yazdi
BTIG
BTIG
$24
Buy
99.34%
Upside
Reiterated
08/05/26
Analyst Reiterates Buy on Zevra as Strong Miplyffa Performance Offsets Arimoclomol Setback; $24 Price Target Maintained
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ODTXOdyssey Therapeutics, Inc.
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
GPCRStructure Therapeutics, Inc. Sponsored ADR
AMLXAmylyx Pharmaceuticals Inc
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Zevra Therapeutics

3 Months
Sumant KulkarniCanaccord Genuity
Success Rate
12/18 ratings generated profit
67%
Average Return
+7.06%
Copying Sumant Kulkarni's trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +7.06% per trade.
1 Year
Kristen KluskaCantor Fitzgerald
Success Rate
9/10 ratings generated profit
90%
Average Return
+20.39%
Copying Kristen Kluska's trades and holding each position for 1 Year would result in 90.00% of your transactions generating a profit, with an average return of +20.39% per trade.
2 Years
Sumant KulkarniCanaccord Genuity
Success Rate
17/18 ratings generated profit
94%
Average Return
+42.09%
Copying Sumant Kulkarni's trades and holding each position for 2 Years would result in 94.44% of your transactions generating a profit, with an average return of +42.09% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ZVRA Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
9
13
16
21
25
Buy
2
3
3
4
4
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
11
16
19
25
29
In the current month, ZVRA has received 29 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. ZVRA average Analyst price target in the past 3 months is 25.25.
Each month's total comprises the sum of three months' worth of ratings.

ZVRA Financial Forecast

ZVRA Earnings Forecast

Next quarter’s earnings estimate for ZVRA is $0.16 with a range of $0.11 to $0.21. The previous quarter’s EPS was $0.14. ZVRA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year ZVRA has Performed in-line its overall industry.
Next quarter’s earnings estimate for ZVRA is $0.16 with a range of $0.11 to $0.21. The previous quarter’s EPS was $0.14. ZVRA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year ZVRA has Performed in-line its overall industry.

ZVRA Sales Forecast

Next quarter’s sales forecast for ZVRA is $37.08M with a range of $34.70M to $40.91M. The previous quarter’s sales results were $39.66M. ZVRA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year ZVRA has Performed in-line its overall industry.
Next quarter’s sales forecast for ZVRA is $37.08M with a range of $34.70M to $40.91M. The previous quarter’s sales results were $39.66M. ZVRA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year ZVRA has Performed in-line its overall industry.

ZVRA Stock Forecast FAQ

What is ZVRA’s average 12-month price target, according to analysts?
Based on analyst ratings, Zevra Therapeutics’s 12-month average price target is 25.25.
    What is ZVRA’s upside potential, based on the analysts’ average price target?
    Zevra Therapeutics has 109.72% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ZVRA a Buy, Sell or Hold?
          Zevra Therapeutics has a consensus rating of Strong Buy which is based on 9 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Zevra Therapeutics’s price target?
            The average price target for Zevra Therapeutics is 25.25. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $35.00 ,the lowest forecast is $20.00. The average price target represents 109.72% Increase from the current price of $12.04.
              What do analysts say about Zevra Therapeutics?
              Zevra Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.
                How can I buy shares of ZVRA?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.